Dubai Telegraph - The winding, fitful path to weight loss drug Ozempic

EUR -
AED 3.897588
AFN 71.62565
ALL 97.2537
AMD 411.203272
ANG 1.913552
AOA 968.293905
ARS 1058.745012
AUD 1.627557
AWG 1.911648
AZN 1.807819
BAM 1.955455
BBD 2.143822
BDT 126.883565
BGN 1.95804
BHD 0.399961
BIF 3075.191117
BMD 1.061143
BND 1.421016
BOB 7.363046
BRL 6.140859
BSD 1.061762
BTN 89.662386
BWP 14.445129
BYN 3.47465
BYR 20798.394027
BZD 2.140123
CAD 1.480899
CDF 3044.418227
CHF 0.936171
CLF 0.037916
CLP 1046.211864
CNY 7.674607
COP 4713.329932
CRC 543.329624
CUC 1.061143
CUP 28.120278
CVE 110.729863
CZK 25.391006
DJF 188.586074
DKK 7.45901
DOP 63.933705
DZD 141.600995
EGP 52.213665
ETB 128.927564
FJD 2.404653
GBP 0.833113
GEL 2.907297
GHS 17.418672
GMD 75.870655
GNF 9158.721715
GTQ 8.204937
GYD 222.11867
HKD 8.254453
HNL 26.592299
HTG 139.651911
HUF 410.802767
IDR 16762.975014
ILS 3.985736
INR 89.551307
IQD 1390.096744
IRR 44679.406949
ISK 147.498979
JMD 168.710198
JOD 0.752456
JPY 164.232506
KES 137.417871
KGS 91.474118
KHR 4302.933102
KMF 488.523524
KRW 1494.624597
KWD 0.326418
KYD 0.884785
KZT 526.901752
LAK 23302.690344
LBP 95078.373015
LKR 310.479784
LRD 196.6824
LSL 19.280981
LTL 3.133278
LVL 0.641875
LYD 5.162473
MAD 10.527599
MDL 19.005538
MGA 4923.70171
MKD 61.609117
MMK 3446.549617
MOP 8.506897
MRU 42.335075
MUR 49.990475
MVR 16.405298
MWK 1841.082561
MXN 21.872228
MYR 4.708282
MZN 67.833584
NAD 19.281345
NGN 1774.951722
NIO 39.023514
NOK 11.770787
NPR 143.459418
NZD 1.793877
OMR 0.40856
PAB 1.061762
PEN 4.000181
PGK 4.260222
PHP 62.350627
PKR 295.050664
PLN 4.354234
PYG 8295.534619
QAR 3.863355
RON 4.976865
RSD 116.971889
RUB 104.249364
RWF 1445.806728
SAR 3.987149
SBD 8.850728
SCR 14.422986
SDG 638.273057
SEK 11.587852
SGD 1.421194
SLE 24.247182
SOS 605.912547
SRD 37.389344
STD 21963.508396
SVC 9.290797
SZL 18.707922
THB 36.991474
TJS 11.2858
TMT 3.72461
TND 3.339947
TOP 2.485304
TRY 36.467135
TTD 7.215065
TWD 34.443094
TZS 2824.618246
UAH 43.973732
UGX 3901.494647
USD 1.061143
UYU 44.764202
UZS 13614.459211
VES 47.430329
VND 26899.963703
XAF 655.872046
XCD 2.867791
XDR 0.799896
XOF 645.174431
XPF 119.331742
YER 265.099936
ZAR 19.251725
ZMK 9551.56176
ZMW 28.906256
ZWL 341.687469
  • RBGPF

    0.0300

    60.22

    +0.05%

  • BCC

    -2.0100

    141.13

    -1.42%

  • CMSC

    -0.1800

    24.54

    -0.73%

  • BCE

    -0.1600

    27.69

    -0.58%

  • RYCEF

    -0.1700

    7.16

    -2.37%

  • SCS

    0.0200

    13.67

    +0.15%

  • CMSD

    -0.2100

    24.75

    -0.85%

  • NGG

    -1.2400

    62.9

    -1.97%

  • RIO

    -1.4000

    61.2

    -2.29%

  • JRI

    -0.3000

    13.22

    -2.27%

  • GSK

    -0.8300

    35.52

    -2.34%

  • RELX

    -1.2100

    46.59

    -2.6%

  • AZN

    0.4000

    65.19

    +0.61%

  • BTI

    0.0900

    35.24

    +0.26%

  • BP

    -0.7600

    28.16

    -2.7%

  • VOD

    -0.8500

    8.47

    -10.04%

The winding, fitful path to weight loss drug Ozempic
The winding, fitful path to weight loss drug Ozempic / Photo: Chris Taggart - The Rockefeller University/AFP

The winding, fitful path to weight loss drug Ozempic

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so what was that journey like for the scientists involved?

Text size:

Joel Habener of Massachusetts General Hospital and Svetlana Mojsov of The Rockefeller University, who are being honored with the prestigious Lasker Award for their role in the research, spoke to AFP about how they made the discoveries that changed the way we think about weight.

The pair will share the award -- often considered a predictor of future Nobel success -- as well as an honorarium of $250,000 with Lotte Bjerre Knudsen of Novo Nordisk, which manufactures Ozempic.

- Early molecular biology -

Obesity has escalated into a global health crisis, affecting 900 million people worldwide -- including over 40 percent of Americans and nearly a quarter of Europeans.

But back in the mid-1970s, when Habener, now 87, began his career as a physician-scientist, his curiosity was focused on diabetes.

He was particularly interested in the pancreatic hormone glucagon, known for raising blood sugar levels -- the opposite effect of insulin, which was already used as a treatment for diabetes.

By understanding and potentially modulating glucagon's effects, Habener believed he could uncover new ways to manage diabetes.

To pursue this, he turned to the emerging field of molecular biology, aiming to isolate and clone the gene that encodes glucagon.

- Fortuitous turn to fish -

But he quickly hit a roadblock: the US National Institutes of Health had just banned the type of research he planned to conduct on mammalian genes.

This pushed him to pivot to studying the anglerfish, a creature with a unique endocrine organ outside the pancreas.

"It turned out to be a godsend in terms of simplicity," he recalled, describing the eureka moment when he isolated a precursor protein that gave rise to glucagon -- as well as a second hormone that resembled glucagon.

Though Habener didn't realize its significance at the time, this turned out to be the fish-equivalent of "GLP-1," the foundation for today's diabetes and obesity drugs.

"That's what's beautiful about discovery research," he said. "By exploring the unknown, you get surprises."

- Identifying GLP-1's potential -

Mojsov, who emigrated from Yugoslavia, took the early discoveries made by Habener and others further with several important contributions.

Poring over the hormone's structure, she correctly predicted the active form of GLP-1 and devised innovative chemistry methods to synthesize it.

She also proposed that GLP-1 would be released in the intestines and act to trigger insulin production. Together with Habener and others, she proved this theory through lab experiments and human trials, identifying its therapeutic potential.

"I was sure it would be a good drug for diabetes," said the 76-year-old. However, at the time, there was no scientific evidence that hormones could regulate weight.

It was only later studies by Habener, Mojsov, and others that revealed GLP-1's ability to slow stomach emptying and its interaction with receptors in the brain, helping to curb appetite and possibly even address substance addictions.

- New era of treatments -

Starting in the 1990s, Knudsen, the head of GLP-1 therapeutics at Novo Nordisk, and her team built on these breakthroughs to develop treatments for diabetes (Ozempic) and obesity (Wegovy), extending the drug's therapeutic effects from just a few hours to over a week.

"Now we can see that GLP-1 actually has a much broader spectrum of health benefits," said Mojsov, though she laughs off the "miracle drug" label.

Obese patients "lose a lot of weight but also their muscle mass, and that's also very serious," she stressed. "I think it should never be taken for cosmetic reasons."

GLP-1 drugs have now been approved for treating cardiovascular disease, and emerging evidence suggests they may offer protective effects against dementia.

Though the exact mechanism remains unclear, Habener suggests their ability to suppress inflammatory pathways might be the common link.

As for the future, Mojsov is optimistic. She foresees a new generation of similar drugs that will further minimize side effects and target an even broader range of diseases.

A.Al-Mehrazi--DT